Preanesthetic Medication

Introduction/Overview

Background

Preanesthetic medication constitutes the pharmacologic intervention administered prior to the induction of general or regional anesthesia. The primary objectives are to attenuate perioperative anxiety, provide sedation, reduce the hemodynamic response to airway manipulation and surgical stimuli, optimize analgesia, and prevent postoperative nausea and vomiting (PONV). The selection of agents is driven by patient characteristics, surgical factors, and institutional protocols. A systematic approach to preanesthetic pharmacotherapy is critical for achieving hemodynamic stability, minimizing drug-related complications, and enhancing patient satisfaction.

Clinical Relevance

Inadequate preoperative preparation may lead to exaggerated sympathetic responses, airway complications, and postoperative distress. Conversely, inappropriate agent selection or dosing can precipitate respiratory depression, hypotension, or delirium. Therefore, mastery of preanesthetic pharmacology is indispensable for clinicians involved in perioperative care, including anesthesiologists, surgeons, and pharmacists.

Learning Objectives

• Identify and classify the principal drug classes employed in preanesthetic care.
• Explain the pharmacodynamic and pharmacokinetic properties that guide agent selection.
• Recognize therapeutic indications, contraindications, and common adverse events associated with preanesthetic medications.
• Evaluate potential drug–drug interactions and special population considerations.
• Summarize evidence-based strategies for optimizing preoperative pharmacologic management.

Classification

Drug Classes by Therapeutic Purpose

• Anxiolytic‑sedatives – benzodiazepines, alpha‑2 adrenergic agonists.
• Analgesics – opioids, non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Anticholinergics – atropine, glycopyrrolate.
• Antiemetics – serotonin 5‑HT₃ antagonists, dopamine antagonists, neurokinin‑1 antagonists.
• Adjunctive agents – beta‑blockers, clonidine, dexmedetomidine, corticosteroids.

Chemical Classification

• Benzodiazepines: imidazobenzodiazepine core; examples include diazepam, midazolam.
• Opioids: morphine‑type alkaloids, synthetic derivatives (fentanyl, sufentanil, remifentanil).
• Alpha‑2 agonists: imidazoline derivatives (clonidine, dexmedetomidine).
• Anticholinergics: alkaloid derivatives (atropine), synthetic tertiary amines (glycopyrrolate).
• Antiemetics: phenothiazine ring (diphenhydramine), piperazine scaffold (metoclopramide), indole bis‑piperidine (ondansetron).

Mechanism of Action

Anxiolytic‑Sedatives

Benzodiazepines

Benzodiazepines bind to the γ‑aminobutyric acid type A (GABA_A) receptor complex at a distinct site, enhancing the affinity of GABA for its receptor. This potentiation increases chloride influx, hyperpolarizing neuronal membranes and producing rapid anxiolysis, amnesia, and sedation. The onset is typically within 5–10 minutes when administered intravenously.

Alpha‑2 Adrenergic Agonists

Alpha‑2 agonists act as partial agonists at presynaptic α‑2A receptors in the locus coeruleus. Activation reduces norepinephrine release, thereby decreasing sympathetic tone. The sedative effect is mediated through inhibition of cortical excitatory pathways. Dexmedetomidine demonstrates higher selectivity for α‑2A over α‑2B receptors compared with clonidine, contributing to a more favorable hemodynamic profile.

Analgesics

Opioids

Opioids bind to μ, κ, and δ opioid receptors located in the central nervous system and peripheral tissues. Activation of μ receptors results in inhibition of voltage‑gated calcium channels and activation of potassium channels, reducing neuronal excitability. The analgesic and respiratory depressant effects are dose‑dependent and mediated primarily through μ‑receptor activation.

NSAIDs

NSAIDs inhibit cyclo‑oxygenase (COX) enzymes, reducing prostaglandin synthesis. Prostaglandins sensitize nociceptors and mediate inflammatory pain. By lowering prostaglandin levels, NSAIDs diminish peripheral nociceptive input and thereby reduce postoperative pain.

Anticholinergics

Anticholinergics block muscarinic acetylcholine receptors (M₁–M₅), preventing parasympathetic stimulation of the airway, salivary glands, and gastrointestinal tract. This leads to decreased secretions and bronchial smooth‑muscle tone reduction, facilitating airway management and reducing aspiration risk.

Antiemetics

Serotonin 5‑HT₃ Antagonists

5‑HT₃ antagonists inhibit serotonin‐mediated signaling within the chemoreceptor trigger zone (CTZ) and the vagal afferents of the gut, thereby preventing the emetic reflex. Potent antagonism at the CTZ is associated with effective PONV prophylaxis.

Dopamine Antagonists

Dopamine antagonists block D₂ receptors in the CTZ, reducing emetic signaling. The blockade in the nigrostriatal pathway can lead to extrapyramidal side effects, such as dystonia or akathisia.

Neurokinin‑1 Antagonists

Neurokinin‑1 antagonists inhibit substance P binding to NK1 receptors in the medullary vomiting center, providing additive prophylaxis when combined with 5‑HT₃ antagonists.

Adjunctive Agents

Beta‑Blockers

Beta‑adrenergic blockers inhibit sympathetic catecholamine release at β₁ and β₂ receptors, attenuating tachycardia and hypertension associated with laryngoscopy and intubation. The blockade of β₁ receptors reduces myocardial oxygen demand.

Corticosteroids

Glucocorticoids downregulate inflammatory mediators and cytokines, thereby decreasing the incidence of PONV and postoperative sore throat. Their anti‑inflammatory effects also reduce tissue edema and pain.

Pharmacokinetics

Absorption

Most preanesthetic agents are administered intravenously (IV) to guarantee rapid onset and precise titration. Intramuscular (IM) routes are occasionally employed for benzodiazepines (e.g., diazepam) or for patients unable to receive IV access. Oral premedication may be considered for anxiolytics (e.g., clonazepam) but is limited by variable first‑pass metabolism and delayed onset. The bioavailability of oral benzodiazepines is generally high (≈70–80 %), whereas oral opioids exhibit variable absorption due to hepatic first‑pass effects.

Distribution

Agents with high lipid solubility, such as midazolam and fentanyl, cross the blood‑brain barrier rapidly, achieving peak central nervous system concentrations within 1–2 minutes. The volume of distribution (V_d) for benzodiazepines ranges from 0.4 to 0.6 L/kg, whereas fentanyl’s V_d is approximately 3 L/kg. Protein binding is significant for many agents (e.g., 80–90 % for midazolam, 70–80 % for fentanyl), influencing the free fraction available for pharmacologic action. Plasma protein binding is reduced in hypoalbuminemic patients, potentially increasing drug exposure.

Metabolism

Cytochrome P450 (CYP) enzymes mediate metabolism for most preanesthetic agents. Midazolam is primarily metabolized by CYP3A4 to 1‑hydroxymidazolam, an inactive metabolite. Opioid metabolism varies: fentanyl undergoes CYP3A4‑mediated N‑dealkylation, while remifentanil is hydrolyzed by nonspecific plasma and tissue esterases, conferring a very short half‑life. Dexmedetomidine is metabolized by hepatic glucuronidation (UGT1A4) and CYP2A6. Anticholinergics (e.g., glycopyrrolate) undergo minimal hepatic metabolism and are predominantly excreted unchanged via the kidneys.

Excretion

Renal excretion predominates for glycopyrrolate, ondansetron, and many opioids (e.g., morphine metabolites). Hepatic excretion of glucuronide conjugates is significant for morphine and its metabolites. The elimination half‑life (t_½) varies: midazolam 2–4 h; fentanyl 2–4 h; remifentanil <10 min; dexmedetomidine 2–3 h; chlorpheniramine 18–20 h. Dosage calculations should consider renal and hepatic function, with adjustments required for impaired clearance.

Dosing Considerations

Standard IV dosing regimens are typically weight‑based. For instance, midazolam 0.05–0.1 mg/kg for sedation; fentanyl 1–2 µg/kg for analgesia; glycopyrrolate 0.01 mg/kg to reduce secretions. In elderly or frail patients, lower initial doses and slower titration are prudent to avoid oversedation and hypotension. In pediatric populations, dosing must account for developmental pharmacokinetics, with particular caution for agents that are cleared by esterases (e.g., remifentanil) due to higher esterase activity in children.

Therapeutic Uses/Clinical Applications

Anxiolysis and Sedation

Benzodiazepines and alpha‑2 agonists are routinely used to alleviate preoperative anxiety and to produce sedation that facilitates airway management. The choice between a benzodiazepine and an alpha‑2 agonist often hinges on the desired hemodynamic profile, the presence of comorbid conditions, and institutional preference.

Analgesia

Opioids are administered preoperatively to reduce intraoperative nociceptive transmission and to provide rapid postoperative pain control. NSAIDs are also employed for multimodal analgesia, with a particular emphasis on reducing opioid consumption and mitigating opioid‑related adverse events.

Secretions Control

Anticholinergics are indicated to minimize airway and gastrointestinal secretions, thereby decreasing the risk of aspiration and facilitating the insertion of airway devices. Glycopyrrolate is favored over atropine in many settings due to its reduced penetration of the blood‑brain barrier, limiting central anticholinergic effects.

Prevention of PONV

Serotonin 5‑HT₃ antagonists, dopamine antagonists, and neurokinin‑1 antagonists are employed prophylactically in patients at high risk of PONV. Combination therapy with multiple mechanisms of action has been shown to provide superior protection, especially in patients with multiple risk factors (e.g., female sex, nonsmoking status, history of motion sickness).

Hemodynamic Stability

Beta‑blockers and selective alpha‑2 agonists are utilized to blunt the sympathetic surge associated with laryngoscopy and intubation. Corticosteroids may also contribute to hemodynamic stability by attenuating inflammatory responses and reducing capillary permeability.

Adjunctive Uses

Glucocorticoids are administered to reduce postoperative nausea, vomiting, and sore throat. Opioid-sparing strategies, such as preemptive analgesia with NSAIDs or regional techniques, are increasingly adopted to decrease opioid requirements and associated complications.

Adverse Effects

Common Side Effects

• Respiratory depression – prominent with opioids and benzodiazepines; incidence increases with higher doses or combined sedatives.
• Hypotension – particularly with high‑dose benzodiazepines, beta‑blockers, and alpha‑2 agonists due to vasodilation and decreased cardiac output.
• Bradycardia – observed with dexmedetomidine and clonidine; may necessitate anticholinergic support.
• Anticholinergic effects – dry mouth, blurred vision, urinary retention, tachycardia; more pronounced with atropine.
• Gastrointestinal disturbances – nausea, vomiting, constipation; frequently associated with opioids.

Serious or Rare Adverse Reactions

• Severe respiratory depression – potentially fatal if not promptly addressed; requires airway support and reversal agents (e.g., naloxone, flumazenil).
• Cardiac arrhythmias – QT prolongation with certain antihistamines and antiemetics; ventricular arrhythmias may occur in susceptible patients.
• Neuroleptic malignant syndrome – rare with high‑dose benzodiazepines or dopamine antagonists; characterized by hyperthermia, rigidity, autonomic instability.
• Allergic reactions – anaphylaxis or anaphylactoid responses to anticholinergics or opioids; prompt epinephrine administration is critical.

Black Box Warnings

Opioids carry a black‑box warning for respiratory depression and potential for dependence. Benzodiazepines are associated with a black‑box warning for severe respiratory depression when combined with other CNS depressants. Dexmedetomidine is contraindicated in patients with significant bradycardia or conduction abnormalities due to its potent vagotonic effects.

Drug Interactions

Major Drug‑Drug Interactions

• CYP3A4 inhibitors/inducers – agents such as ketoconazole, rifampin, or carbamazepine alter the metabolism of benzodiazepines (midazolam) and opioids (fentanyl), necessitating dose adjustments.
• Serotonergic agents – concomitant use of SSRIs or SNRIs with serotonin 5‑HT₃ antagonists may increase the risk of serotonin syndrome, though the latter is rare.
• Anticholinergic load – combining multiple anticholinergic agents (e.g., glycopyrrolate with diphenhydramine) may precipitate severe central and peripheral anticholinergic toxicity.
• Opioid–benzodiazepine synergy – additive CNS depression leads to heightened risk of respiratory failure.
• Beta‑blocker and clonidine interaction – dual blockade of sympathetic tone can cause profound hypotension and bradycardia.

Contraindications

Known hypersensitivity to the drug or its excipients constitutes an absolute contraindication. In patients with severe hepatic impairment, the use of metabolically dependent agents (e.g., midazolam) is discouraged, and alternative agents with minimal hepatic metabolism should be preferred. Renal failure may necessitate avoidance or dose reduction of renally excreted drugs such as glycopyrrolate and ondansetron.

Special Considerations

Pregnancy and Lactation

Cross‑placental transfer of benzodiazepines and opioids is well documented; thus, exposure during the first trimester may be associated with fetal teratogenicity, while exposure in the third trimester may lead to neonatal withdrawal symptoms. Anticholinergics are generally considered safe in pregnancy but may increase maternal urinary retention. Lactation is contraindicated with high‑dose benzodiazepines and opioids due to potential accumulation in nursing infants. Low‑dose dexmedetomidine has limited data; cautious use is advised.

Pediatric Considerations

Pediatric patients demonstrate altered pharmacokinetics, with faster drug clearance for many agents and heightened sensitivity to opioids. Weight‑based dosing is mandatory. The use of benzodiazepines should be limited to short durations due to the risk of increased sedation and respiratory depression. Dexmedetomidine has been employed for sedation in pediatric intensive care settings, with a recommended loading dose of 1 µg/kg over 10 minutes followed by a maintenance infusion of 0.2–0.7 µg/kg/h.

Geriatric Considerations

Age‑associated changes in body composition, reduced hepatic and renal function, and increased sensitivity to CNS depressants necessitate cautious dosing. Benzodiazepines often exhibit prolonged effects in older adults; therefore, lower doses and slower titration are recommended. Glycopyrrolate is preferred over atropine to reduce central anticholinergic effects.

Renal and Hepatic Impairment

In patients with renal insufficiency, glycopyrrolate and ondansetron should be dose‑reduced or avoided. For hepatic impairment, agents primarily cleared by CYP3A4 (e.g., midazolam, fentanyl) require dose adjustment or substitution with agents metabolized by alternative pathways (e.g., remifentanil). Monitoring of drug levels is not routinely performed but may be considered in high‑risk patients.

Summary/Key Points

• Preanesthetic medication aims to reduce anxiety, provide sedation, control secretions, prevent PONV, and stabilize hemodynamics.
• Benzodiazepines and alpha‑2 agonists are the main anxiolytic‑sedative agents; opioids and NSAIDs form the analgesic backbone.
• Anticholinergics, antiemetics, beta‑blockers, and corticosteroids serve adjunctive roles in optimizing perioperative conditions.
• Drug selection should consider pharmacodynamics, pharmacokinetics, patient comorbidities, and potential interactions.
• Monitoring for respiratory depression, hypotension, bradycardia, and anticholinergic toxicity is essential, with readiness for reversal agents.
• Special populations—pregnant, lactating, pediatric, geriatric, and those with organ dysfunction—require tailored dosing and vigilant observation.
• Multimodal strategies incorporating non‑opioid agents can reduce opioid consumption and associated adverse events.

References

1. Flood P, Rathmell JP, Urman RD. Stoelting's Pharmacology and Physiology in Anesthetic Practice. 6th ed. Philadelphia: Wolters Kluwer; 2022.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.